Loading company financials…
NYSE · Surgical & Medical Instruments & Apparatus · CIK 0000943819
$228.35
-4.98% · delayed 15 min
$32.94B market value
What this company does
RESMED makes medical devices and equipment. It took in $5.65B last year, which makes it a mid-sized company. Of every dollar it sells, about 27 cents is left as profit.
Changed its auditor, in a filing on 2026-08-17.
Form 8-K, item 4.01 · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From RESMED INC's FY2026 annual filing · share price scored separately
Every check behind the three models, and what each one tests
of 9 checks passed
Measured against FY2025, from the 10-K
Improved: +9.9%
$5.15B to $5.65B
Improved: +8.8%
$1.40B to $1.52B
Improved: +1.7 pts
59.4% to
It makes a profit rather than burning through money.
$1.52B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$1.81B cash from operations
It holds more cash than debt, so borrowings are not a pressure.
$809.9M more cash than debt
It passes almost every standard check of financial strength.
Piotroski 8/9
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 5% a year for the next 10 years. Over the last 10 years it grew by about 13% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 27 cents of every dollar of sales as profit, earning $1.52B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 23 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 19% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2026 annual filing
Last year it earned $1.52B and generated $1.81B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-09-01 | 2026-08-31 |
| Major event announcement(8-K) | 2026-08-17 | 2026-08-13 |
Financial figures are from RMD's 10-K for fiscal year 2026 (period ending 2026-06-30), reported under the US GAAP taxonomy. View the source filing.
Nine yes-or-no tests of whether this year's finances improved on last year's.
11.15
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.58
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Improved: -39.3%
$658.4M to $399.4M
Improved: +21.5%
$1.21B to $1.47B
Improved: -1.5%
146.4M to 144.2M
Changed: +73.9%
$89.9M to $156.3M
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 3% and 7%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 8.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 9.9% last year.
No — it holds more cash than debt, with $809.9M left over after paying off every borrowing. For every $1 it owes, it owns $3.77 in assets.
Around average. Investors pay $21.6 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Annual report(10-K) | 2026-08-13 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-06 | 2026-08-06 |
| Major event announcement(8-K) | 2026-07-07 | 2026-06-30 |
| Quarterly report(10-Q) | 2026-05-01 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-24 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-30 |
| Quarterly report(10-Q) | 2026-01-30 | 2025-12-31 |
| Major event announcement(8-K) | 2026-01-29 | 2026-01-29 |
| Major event announcement(8-K) | 2025-11-20 | 2025-11-19 |
| Quarterly report(10-Q) | 2025-10-31 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Shareholder voting information(DEF 14A) | 2025-10-02 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-18 | 2025-08-15 |
| Annual report(10-K) | 2025-08-08 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-01 | 2025-07-28 |
| Major event announcement(8-K) | 2025-07-31 | 2025-07-31 |
| Quarterly report(10-Q) | 2025-04-24 | 2025-03-31 |
| Major event announcement(8-K) | 2025-04-23 | 2025-04-23 |
Coverage from the last 30 days
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
Yahoo Finance ·
ResMed Stock: Analyst Estimates & Ratings
Yahoo Finance ·
23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
Yahoo Finance ·
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
Yahoo Finance ·
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
Yahoo Finance ·
ResMed (RMD) Q4 2026 Earnings Call Transcript
Yahoo Finance ·
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?
Yahoo Finance ·
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
Yahoo Finance ·
ResMed Q4 Earnings Call Highlights
Yahoo Finance ·
Frazier Healthcare Partners Completes Acquisition of MatrixCare, Appoints Jonathan Lujan as Chief Executive Officer
Yahoo Finance ·
2 Profitable Stocks Worth Investigating and 1 We Turn Down
Yahoo Finance ·
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
Yahoo Finance ·
Primary sources and further research